Genetic Medicines Co. Reveals Transformative 'Only-of-Its-Kind' AAV Therapy Milestone

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

On April 16, 2026, MeiraGTx Holdings Plc (MGTX:NASDAQ) released two news items: positive data from its 3-year Phase 1 clinical trial for AAV-hAQP1 and a new underwritten offering of 11,111,111 shares.  

The Phase 1 AQUAx clinical trial was designed to evaluate the safety of MeiraGTx's investigational gene therapy, AAV-hAQP1 ". . . when administered via Stensen's duct to one or both parotid glands in patients who have been diagnosed with grade 2 or 3 radiation-induced xerostomia and who have remained cancer-free for at least five years (or at least two years if HPV+) after receiving radiation treatment for head and neck cancer."

President, CEO, and Ph.D. Alexandria Forbes announced, "The 3-year data shows remarkable maintenance of the unprecedented improvements seen in response to AAV-hAQP1 treatment at 12 months. XQ responses are maintained over 3 years, as is unstimulated saliva flow – the objective measure of the therapy’s mechanism of action. The durability we are seeing with AAV-hAQP1 is extraordinary, particularly following the simple one-time treatment. In addition to the durability of the population data over three years, the consistency of responses within individual patients is also encouraging. This three-year durability data is changing the way AAV-hAQP1 treatment is viewed by physicians, as it is now being regarded as a simple one-time treatment that has disease modifying impact on patients with this lifelong, severely debilitating condition that has no other treatments."

The company also reacquired the drug, bota-vec, into its portfolio. The drug is a late-stage ophthalmology asset, according to H.C. Wainwright & Co., that will undergo Phase 3 trials.

Directly after this news, MeiraGTx released a US$9 offer per ordinary share, with the expectation that gross proceeds would total around US$100 million. After costs, the company plans to use the net proceeds to fund its operating expenses and capital expenditure requirements, including ". . .  potential commercial launches of bota-vec for the treatment of X-linked retinitis pigmentosa and AAV-hAQP1 for the treatment of radiation-induced xerostomia, in each case if approved, into the second half of 2028."

The offering is being joint book managed by BofA Securities and Goldman Sachs & Co. LLC, with Raymond James acting as co-manager. The offer was met and closed late last week.

MeiraGTx considers itself a ". . . vertically integrated, clinical-stage genetic medicines company with a broad pipeline" and it based in the New York City.

Gene Therapies a Growing Market

There is currently no competition for AAV-hAQP1, and Forbes said in the release that, "Persistent radiation-induced xerostomia is a severe unmet need with a large, well-defined patient population, strong physician enthusiasm, and a simple one-time in-office procedure. We believe AAV-hAQP1 has the potential to be clinically transformative and a very meaningful commercial opportunity."

In December 2025, Yahoo Finance reported that CRISPR-based gene editing tools and novel vector delivery platforms have begun reshaping the therapeutic landscape. The same article valued the global gene therapy market at US$8.85 billion in 2024, with projections of a CAGR advancement of 19.4% from 2025 to 2032. This forecasted valuation leads to projected market highs of US$36.55 billion.  

Biotech and pharmaceuticals, in general, have also shown exponential growth recently. "The global biotechnology market size was estimated at US$1.55 trillion in 2023 and is projected to reach US$3.88 trillion by 2030, growing at a CAGR of 13.96% from 2024 to 2030," said Grandview Research.

Buy Ratings Across the Board

According to Factset:

• Mitchel S. Kapoor for H.C. Wainwright & Co. reiterated its 'Buy' rating for MeiraGTx Holdings Plc. on April 20, 2026, with a target price of US$20.00.
• Christopher Raymond of Raymond James gave the company a 'Buy' rating on April 16, 2026, with a price target of US$27.00.
• Lisa Walker of RBC Capital Markets gave the company a 'Buy' rating on April 16, 2026, with a price target of US24.00.
• Gavin Clark-Gartner for Evercore ISI gave the company a 'Buy'' rating on April 16, 2026, with a price target of US$18.00.
• Daniil Gataulin of Chardan gave the company a 'Buy' rating on April 16, 2026, with a price target of US$35.00.
• Elemer Piros of Lucid Capital Markets gave the company a 'Buy' rating on April 15, 2026, with a price target of US$50.00.
• Allison M. Bratzel of Piper Sandler Companies gave the company a 'Buy' rating on March 26, 2026, with a price target of US$26.00.

In the April 20 research for H.C. Wainwright & Co., Kapoor considered "AAV-hQP1's 3-year durability, bota-vec's return, and financing into 2H28 to sharpen the path to two launches over the next two years."

Analysts Call 2026 Calendar "Stacked"

Senior Analyst Kapoor wrote in Wainwright's research paper that "... we see a stacked 2026-2027 catalyst calendar. MeiraGTx priced 11.1M shares at US$9/share for ~US$100M in gross proceeds late last week; the company said net proceeds together with existing cash should fund operating expenses and capital expenditures, including potential launches of bota-vec and AAV-hAQP1 if approved, into 2H28.

Beyond bota-vec filings and the 2Q27 AQUAx2 readout/BLA timing, AAV-GAD Phase 3 initiation remains expected in 2026 under the Hologen JV, trigeminal neuralgia is also expected to enter the clinic in 2026, and Ribo-leptin remains a candidate for near-term Investigational New Drug (IND) application submission, pending FDA alignment. Milestone optionality from Eli Lilly and Co. (LLY:NYSE), including US$135M in nearer-term milestones within a >US$400M total package, remains incremental to the core commercial setup." 

According to MeiraGTx's investor presentation, the company has four pivotal-stage programs in development. The first is a potential BLA filing in early 2027 for AAV-hQP1's. Next is an AIPL1-Associated Congenital Blindness treatment that could be approved in 2026. Finally, the company is moving into a Phase 3 study for a Parkinson's Disease treatment that could be ready for a BLA filing in 2028.

Ownership & Share Structure¹

MeiraGTx Holdings Plc. has a market cap of US$936.68 million, with 92.56 million shares outstanding. The company's 52-week range is US$4.55-US$11.85.

Institutions hold 57.66% of shares, while Strategic Entities own 13.93%. Management & Insiders own 4.07% of shares, and the remaining 24.34% of shares are held by Retail.